IPDQF: AI 评分 51/100 — AI 分析 (4月 2026)

ImpediMed Limited specializes in medical software technology, focusing on the development, manufacturing, and sales of bioimpedance spectroscopy (BIS) devices and software. Their products, including SOZO, SFB7, and ImpediVET, cater to hospitals, clinics, and veterinary applications across Australia, North America, and internationally.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

ImpediMed Limited is a medical technology company specializing in bioimpedance spectroscopy (BIS) devices like SOZO for lymphedema assessment and fluid status monitoring. Operating in Australia, North America, and internationally, the company targets hospitals, clinics, and veterinary practices, facing competition in the broader medical devices market.

IPDQF是做什么的？

ImpediMed Limited, established in 1999 and headquartered in Pinkenba, Australia, is a medical software technology company focused on developing, manufacturing, and selling bioimpedance spectroscopy (BIS) devices and software services. The company's flagship product, SOZO, is a non-invasive BIS device used for the assessment of lymphedema and fluid status monitoring in heart failure patients. SOZO is designed to provide clinicians with rapid, accurate, and actionable data to improve patient outcomes. In addition to SOZO, ImpediMed offers SFB7, a single-channel, tetrapolar BIS device used to analyze body composition in healthy individuals. This device caters to the health and wellness market, providing detailed insights into body composition metrics. ImpediMed also provides ImpediVET, a single-channel, tetrapolar BIS device tailored for veterinary applications. ImpediVET measures fluid status and tissue composition in animals, assisting veterinarians in diagnosing and managing various conditions. ImpediMed sells its devices to hospitals, clinics, and veterinary practices across Australia, North America, and internationally. The company's technology aims to improve the detection, monitoring, and management of diseases and conditions related to fluid status and body composition.

IPDQF的投资论点是什么？

ImpediMed operates in the medical devices sector with a focus on bioimpedance spectroscopy (BIS) technology. The company's SOZO device targets the lymphedema and heart failure markets, offering potential for growth as awareness and adoption of BIS technology increase. Key value drivers include expanding the installed base of SOZO devices, securing reimbursement coverage for BIS procedures, and demonstrating clinical efficacy through research and publications. However, the company's negative profit margin of -171.3% and negative gross margin of -5.8% indicate financial challenges. Upcoming catalysts include potential regulatory approvals and partnerships. Potential risks include competition from alternative technologies and the need for further clinical validation. Investors should monitor the company's progress in achieving profitability and expanding market share.

IPDQF在哪个行业运营？

ImpediMed operates within the medical devices industry, which is characterized by technological innovation, regulatory scrutiny, and evolving reimbursement landscapes. The market for bioimpedance spectroscopy (BIS) devices is growing, driven by the increasing prevalence of lymphedema, heart failure, and other conditions related to fluid management. Competitors in this space include companies offering alternative technologies for fluid monitoring and body composition analysis. ImpediMed's success depends on its ability to differentiate its products through superior accuracy, ease of use, and clinical validation.

Medical - Devices

Healthcare

IPDQF有哪些增长机遇？

Expansion in Lymphedema Market: The increasing prevalence of lymphedema, a condition characterized by fluid retention and swelling, presents a significant growth opportunity for ImpediMed. The SOZO device is specifically designed for lymphedema assessment, offering a non-invasive and accurate method for early detection and monitoring. The global lymphedema market is projected to reach billions of dollars, providing a substantial addressable market for ImpediMed.
Penetration of Heart Failure Market: Heart failure affects millions of people worldwide, and fluid overload is a common complication. ImpediMed's SOZO device can be used to monitor fluid status in heart failure patients, enabling clinicians to optimize treatment and prevent hospitalizations. The market for heart failure monitoring devices is expanding, driven by the aging population and the increasing burden of cardiovascular disease.
Geographic Expansion: ImpediMed currently operates in Australia, North America, and internationally. Expanding into new geographic markets, such as Europe and Asia, represents a significant growth opportunity. These regions have large populations and increasing healthcare expenditures, creating a favorable environment for the adoption of BIS technology. Successful geographic expansion requires regulatory approvals, distribution partnerships, and localized marketing efforts.
Veterinary Applications: The ImpediVET device caters to the veterinary market, providing veterinarians with a tool to assess fluid status and tissue composition in animals. The market for veterinary medical devices is growing, driven by the increasing pet ownership and the rising demand for advanced veterinary care. Expanding the sales and marketing efforts for ImpediVET can contribute to ImpediMed's overall revenue growth.
Strategic Partnerships: Collaborating with hospitals, clinics, and research institutions can accelerate the adoption of ImpediMed's technology and expand its market reach. Strategic partnerships can involve joint research projects, clinical trials, and co-marketing agreements. These partnerships can help ImpediMed validate the clinical efficacy of its products, generate awareness among healthcare professionals, and access new customer segments.

Market capitalization of $0.03 billion indicates a small-cap company.
Negative P/E ratio of -1.34 suggests the company is currently not profitable.
Profit margin of -171.3% reflects significant losses relative to revenue.
Gross margin of -5.8% indicates that the cost of goods sold exceeds revenue.
Beta of 1.31 suggests the stock is more volatile than the overall market.

IPDQF提供哪些产品和服务？

Develops bioimpedance spectroscopy (BIS) devices.
Manufactures BIS devices for medical and veterinary use.
Sells BIS devices and software services internationally.
Offers SOZO for lymphedema assessment and fluid monitoring.
Provides SFB7 for body composition analysis.
Markets ImpediVET for veterinary fluid status monitoring.

IPDQF如何赚钱？

Sells SOZO devices to hospitals and clinics for lymphedema and heart failure management.
Offers SFB7 devices for body composition analysis in the health and wellness market.
Provides ImpediVET devices to veterinary practices for animal fluid status monitoring.
Generates revenue from device sales and software service subscriptions.

Hospitals and clinics using SOZO for lymphedema and heart failure management.
Healthcare professionals using SFB7 for body composition analysis.
Veterinary practices using ImpediVET for animal fluid status monitoring.
Patients benefiting from improved disease detection and monitoring.

Proprietary bioimpedance spectroscopy (BIS) technology.
Established presence in the lymphedema and heart failure markets.
SOZO device with unique features for fluid status monitoring.
ImpediVET device tailored for veterinary applications.

什么因素可能推动IPDQF股价上涨？

Ongoing: Expansion of SOZO device sales in the lymphedema market.
Ongoing: Increasing adoption of BIS technology for heart failure monitoring.
Upcoming: Potential regulatory approvals for new applications of SOZO.
Upcoming: Strategic partnerships with hospitals and clinics.
Ongoing: Publication of clinical studies supporting the efficacy of ImpediMed's products.

IPDQF的主要风险是什么？

Potential: Competition from alternative technologies for fluid monitoring.
Potential: Regulatory hurdles and reimbursement challenges.
Ongoing: Dependence on key products and limited financial resources.
Potential: Economic downturn affecting healthcare spending.
Ongoing: Negative profit margin and gross margin.

IPDQF的核心优势是什么？

Proprietary bioimpedance spectroscopy (BIS) technology.
SOZO device for lymphedema and heart failure assessment.
ImpediVET device for veterinary applications.
Established presence in key markets.

IPDQF的劣势是什么？

Negative profit margin and gross margin.
Limited financial resources.
Dependence on key products.
Small market capitalization.

IPDQF有哪些机遇？

Expansion in lymphedema and heart failure markets.
Geographic expansion into new regions.
Strategic partnerships with hospitals and clinics.
Increasing adoption of BIS technology.

IPDQF面临哪些威胁？

Competition from alternative technologies.
Regulatory hurdles and reimbursement challenges.
Economic downturn affecting healthcare spending.
Technological obsolescence.

IPDQF的竞争对手是谁？

BBIXF — Unknown — (BBIXF)
CLIFF — Unknown — (CLIFF)
CLYYF — Unknown — (CLYYF)
CNTMF — Unknown — (CNTMF)
ELXMF — Unknown — (ELXMF)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Parmjot Bains
Headquarters: Pinkenba, AU
Employees: 83
Founded: 2012

AI Insight

AI analysis pending for IPDQF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does ImpediMed Limited do?

ImpediMed Limited is a medical technology company that develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services. Its primary product, SOZO, is used for the assessment of lymphedema and fluid status monitoring in heart failure patients. The company also offers SFB7 for body composition analysis and ImpediVET for veterinary applications. ImpediMed's technology aims to improve the detection, monitoring, and management of diseases and conditions related to fluid status and body composition, targeting hospitals, clinics, and veterinary practices.

What do analysts say about IPDQF stock?

AI analysis is pending for IPDQF. Without current analyst ratings, it is difficult to provide a consensus view. However, key valuation metrics include a negative P/E ratio, reflecting current losses, and a small market capitalization. Growth considerations revolve around expanding the installed base of SOZO devices, securing reimbursement coverage, and demonstrating clinical efficacy. Investors should monitor the company's progress in achieving profitability and expanding market share before making investment decisions.

What are the main risks for IPDQF?

The main risks for ImpediMed include competition from alternative technologies for fluid monitoring, regulatory hurdles and reimbursement challenges, and its dependence on key products. The company's negative profit and gross margins indicate financial vulnerability. Additionally, its small market capitalization and limited financial resources pose challenges to its growth strategy. Economic downturns affecting healthcare spending could also impact its revenue. Investors should carefully consider these risks before investing in IPDQF.